These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. Zaitseva MB; Lee S; Rabin RL; Tiffany HL; Farber JM; Peden KW; Murphy PM; Golding H J Immunol; 1998 Sep; 161(6):3103-13. PubMed ID: 9743377 [TBL] [Abstract][Full Text] [Related]
3. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4. Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179 [TBL] [Abstract][Full Text] [Related]
4. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4. Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651 [TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. Hesselgesser J; Liang M; Hoxie J; Greenberg M; Brass LF; Orsini MJ; Taub D; Horuk R J Immunol; 1998 Jan; 160(2):877-83. PubMed ID: 9551924 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Ghezzi S; Noonan DM; Aluigi MG; Vallanti G; Cota M; Benelli R; Morini M; Reeves JD; Vicenzi E; Poli G; Albini A Biochem Biophys Res Commun; 2000 Apr; 270(3):992-6. PubMed ID: 10772939 [TBL] [Abstract][Full Text] [Related]
9. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies. Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150 [TBL] [Abstract][Full Text] [Related]
10. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 infection of Langerhans cells in a reconstructed vaginal mucosa. Sivard P; Berlier W; Picard B; Sabido O; Genin C; Misery L J Infect Dis; 2004 Jul; 190(2):227-35. PubMed ID: 15216455 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. Rubbert A; Combadiere C; Ostrowski M; Arthos J; Dybul M; Machado E; Cohn MA; Hoxie JA; Murphy PM; Fauci AS; Weissman D J Immunol; 1998 Apr; 160(8):3933-41. PubMed ID: 9558100 [TBL] [Abstract][Full Text] [Related]
13. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. BouHamdan M; Strayer DS; Wei D; Mukhtar M; Duan LX; Hoxie J; Pomerantz RJ Gene Ther; 2001 Mar; 8(5):408-18. PubMed ID: 11313818 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336 [TBL] [Abstract][Full Text] [Related]
16. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Princen K; Schols D Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254 [TBL] [Abstract][Full Text] [Related]
17. Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4. Taub DD; Mikovits JA; Nilsson G; Schaffer EM; Key ML; Petrow-Sadowski C; Ruscetti FW Cell Immunol; 2004 Aug; 230(2):65-80. PubMed ID: 15598422 [TBL] [Abstract][Full Text] [Related]
18. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865 [TBL] [Abstract][Full Text] [Related]
19. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415 [TBL] [Abstract][Full Text] [Related]